1 SJ Berry, DS Coffey, PC Walsh, LL Ewing. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-479
2 JC Nickel. Inflammation and benign prostatic hyperplasia. Urol Clin North Am. 2008;35:109-115 Crossref
3 W Bushman. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36:403-415 Crossref
4 B Chughtai, R Lee, A Te, S Kaplan. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011;13:147-150
5 F Di Silverio, V Gentile, A De Matteis, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43:164-175 Crossref
6 JC Nickel, CG Roehrborn, MP O'Leary, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54:1379-1384Crossref
7 G Robert, A Descazeaud, N Nicolaïew, et al. Inflammation in prostatic tissue is associated with symptomatic BPH, IPSS and prostate volume [abstract 1410]!. J Urol. 2009;181(Suppl):504 Crossref
8 B Djavan. The correlation between inflammation, BPH and prostate cancer. Eur Urol Suppl. 2009;8:863-864 Crossref
9 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
10 C De Nunzio, W Aronson, SJ Freedland, E Giovannucci, JK Parsons. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560-570 Crossref
11 V Ficarra. Is chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)?. BJU Int. 2013;112:421-422 Crossref
12 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
13 G Kramer, D Mitteregger, M Marberger. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?. Eur Urol. 2007;51:1202-1216 Crossref
14 PF Engelhardt, S Seklehner, H Brustmann, C Riedl, L Lusuardi. Tumor necrosis factor-α expression in patients with obstructive benign prostatic hyperplasia is associated with a higher incidence of asymptomatic inflammatory prostatitis NIH category IV and prostatic calcification. Scand J Urol. 2015 May 10;:1-7 [Epub ahead of print]. Crossref
15 R Bartoletti. Chronic inflammatory infiltrate and BPH: what do we know?. Eur Urol Suppl. 2013;12:99-102 Crossref
16 JA Schalken. Inflammation in the pathophysiology of benign prostatic hypertrophy. Eur Urol Suppl. 2015;14:e1455-e1458
17 JC Nickel. Role of prostatic inflammation in the clinical presentation of benign prostatic hyperplasia. Eur Urol Suppl. 2015;14:e1459-e1463
18 V Ficarra, S Sekulovic, F Zattoni, M Zazzera, G Novara. Why and how to evaluate chronic prostatic inflammation. Eur Urol Suppl. 2013;12:110-115 Crossref
19 A de La Taille. Therapeutic approach: the importance of controlling prostatic inflammation. Eur Urol Suppl. 2013;12:116-122 Crossref
20 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
21 GY Robert. Comparison of the effects of hexanic extract of Serenoa repens (Permixon) and tamsulosin on inflammation biomarkers in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Eur Urol Suppl. 2015;14:e1470-e1474
22 F Scaglione. How to choose the right Serenoa repens extract?. Eur Urol Suppl. 2015;14:e1464-e1469
23 G Laekeman, A Vlietinck. Assessment report on Serenoa repens (W. Bartram) small, fructus. European Medicines Agency Web site. http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2014/12/WC500179593.pdf. Accessed 21 May 2015
1 SJ Berry, DS Coffey, PC Walsh, LL Ewing. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-479
2 JC Nickel. Inflammation and benign prostatic hyperplasia. Urol Clin North Am. 2008;35:109-115 Crossref
3 W Bushman. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36:403-415 Crossref
4 B Chughtai, R Lee, A Te, S Kaplan. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011;13:147-150
5 F Di Silverio, V Gentile, A De Matteis, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43:164-175 Crossref
6 JC Nickel, CG Roehrborn, MP O'Leary, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54:1379-1384Crossref
7 G Robert, A Descazeaud, N Nicolaïew, et al. Inflammation in prostatic tissue is associated with symptomatic BPH, IPSS and prostate volume [abstract 1410]!. J Urol. 2009;181(Suppl):504 Crossref
8 B Djavan. The correlation between inflammation, BPH and prostate cancer. Eur Urol Suppl. 2009;8:863-864 Crossref
9 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
10 C De Nunzio, W Aronson, SJ Freedland, E Giovannucci, JK Parsons. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560-570 Crossref
11 V Ficarra. Is chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)?. BJU Int. 2013;112:421-422 Crossref
12 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
13 G Kramer, D Mitteregger, M Marberger. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?. Eur Urol. 2007;51:1202-1216 Crossref
14 PF Engelhardt, S Seklehner, H Brustmann, C Riedl, L Lusuardi. Tumor necrosis factor-α expression in patients with obstructive benign prostatic hyperplasia is associated with a higher incidence of asymptomatic inflammatory prostatitis NIH category IV and prostatic calcification. Scand J Urol. 2015 May 10;:1-7 [Epub ahead of print]. Crossref
15 R Bartoletti. Chronic inflammatory infiltrate and BPH: what do we know?. Eur Urol Suppl. 2013;12:99-102 Crossref
16 JA Schalken. Inflammation in the pathophysiology of benign prostatic hypertrophy. Eur Urol Suppl. 2015;14:e1455-e1458
17 JC Nickel. Role of prostatic inflammation in the clinical presentation of benign prostatic hyperplasia. Eur Urol Suppl. 2015;14:e1459-e1463
18 V Ficarra, S Sekulovic, F Zattoni, M Zazzera, G Novara. Why and how to evaluate chronic prostatic inflammation. Eur Urol Suppl. 2013;12:110-115 Crossref
19 A de La Taille. Therapeutic approach: the importance of controlling prostatic inflammation. Eur Urol Suppl. 2013;12:116-122 Crossref
20 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
21 GY Robert. Comparison of the effects of hexanic extract of Serenoa repens (Permixon) and tamsulosin on inflammation biomarkers in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Eur Urol Suppl. 2015;14:e1470-e1474
22 F Scaglione. How to choose the right Serenoa repens extract?. Eur Urol Suppl. 2015;14:e1464-e1469
23 G Laekeman, A Vlietinck. Assessment report on Serenoa repens (W. Bartram) small, fructus. European Medicines Agency Web site. http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2014/12/WC500179593.pdf. Accessed 21 May 2015
1 SJ Berry, DS Coffey, PC Walsh, LL Ewing. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-479
2 JC Nickel. Inflammation and benign prostatic hyperplasia. Urol Clin North Am. 2008;35:109-115 Crossref
3 W Bushman. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36:403-415 Crossref
4 B Chughtai, R Lee, A Te, S Kaplan. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011;13:147-150
5 F Di Silverio, V Gentile, A De Matteis, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43:164-175 Crossref
6 JC Nickel, CG Roehrborn, MP O'Leary, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54:1379-1384Crossref
7 G Robert, A Descazeaud, N Nicolaïew, et al. Inflammation in prostatic tissue is associated with symptomatic BPH, IPSS and prostate volume [abstract 1410]!. J Urol. 2009;181(Suppl):504 Crossref
8 B Djavan. The correlation between inflammation, BPH and prostate cancer. Eur Urol Suppl. 2009;8:863-864 Crossref
9 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
10 C De Nunzio, W Aronson, SJ Freedland, E Giovannucci, JK Parsons. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560-570 Crossref
11 V Ficarra. Is chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)?. BJU Int. 2013;112:421-422 Crossref
12 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
13 G Kramer, D Mitteregger, M Marberger. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?. Eur Urol. 2007;51:1202-1216 Crossref
14 PF Engelhardt, S Seklehner, H Brustmann, C Riedl, L Lusuardi. Tumor necrosis factor-α expression in patients with obstructive benign prostatic hyperplasia is associated with a higher incidence of asymptomatic inflammatory prostatitis NIH category IV and prostatic calcification. Scand J Urol. 2015 May 10;:1-7 [Epub ahead of print]. Crossref
15 R Bartoletti. Chronic inflammatory infiltrate and BPH: what do we know?. Eur Urol Suppl. 2013;12:99-102 Crossref
16 JA Schalken. Inflammation in the pathophysiology of benign prostatic hypertrophy. Eur Urol Suppl. 2015;14:e1455-e1458
17 JC Nickel. Role of prostatic inflammation in the clinical presentation of benign prostatic hyperplasia. Eur Urol Suppl. 2015;14:e1459-e1463
18 V Ficarra, S Sekulovic, F Zattoni, M Zazzera, G Novara. Why and how to evaluate chronic prostatic inflammation. Eur Urol Suppl. 2013;12:110-115 Crossref
19 A de La Taille. Therapeutic approach: the importance of controlling prostatic inflammation. Eur Urol Suppl. 2013;12:116-122 Crossref
20 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
21 GY Robert. Comparison of the effects of hexanic extract of Serenoa repens (Permixon) and tamsulosin on inflammation biomarkers in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Eur Urol Suppl. 2015;14:e1470-e1474
22 F Scaglione. How to choose the right Serenoa repens extract?. Eur Urol Suppl. 2015;14:e1464-e1469
23 G Laekeman, A Vlietinck. Assessment report on Serenoa repens (W. Bartram) small, fructus. European Medicines Agency Web site. http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2014/12/WC500179593.pdf. Accessed 21 May 2015
1 SJ Berry, DS Coffey, PC Walsh, LL Ewing. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-479
2 JC Nickel. Inflammation and benign prostatic hyperplasia. Urol Clin North Am. 2008;35:109-115 Crossref
3 W Bushman. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36:403-415 Crossref
4 B Chughtai, R Lee, A Te, S Kaplan. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011;13:147-150
5 F Di Silverio, V Gentile, A De Matteis, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43:164-175 Crossref
6 JC Nickel, CG Roehrborn, MP O'Leary, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54:1379-1384Crossref
7 G Robert, A Descazeaud, N Nicolaïew, et al. Inflammation in prostatic tissue is associated with symptomatic BPH, IPSS and prostate volume [abstract 1410]!. J Urol. 2009;181(Suppl):504 Crossref
8 B Djavan. The correlation between inflammation, BPH and prostate cancer. Eur Urol Suppl. 2009;8:863-864 Crossref
9 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
10 C De Nunzio, W Aronson, SJ Freedland, E Giovannucci, JK Parsons. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560-570 Crossref
11 V Ficarra. Is chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)?. BJU Int. 2013;112:421-422 Crossref
12 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
13 G Kramer, D Mitteregger, M Marberger. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?. Eur Urol. 2007;51:1202-1216 Crossref
14 PF Engelhardt, S Seklehner, H Brustmann, C Riedl, L Lusuardi. Tumor necrosis factor-α expression in patients with obstructive benign prostatic hyperplasia is associated with a higher incidence of asymptomatic inflammatory prostatitis NIH category IV and prostatic calcification. Scand J Urol. 2015 May 10;:1-7 [Epub ahead of print]. Crossref
15 R Bartoletti. Chronic inflammatory infiltrate and BPH: what do we know?. Eur Urol Suppl. 2013;12:99-102 Crossref
16 JA Schalken. Inflammation in the pathophysiology of benign prostatic hypertrophy. Eur Urol Suppl. 2015;14:e1455-e1458
17 JC Nickel. Role of prostatic inflammation in the clinical presentation of benign prostatic hyperplasia. Eur Urol Suppl. 2015;14:e1459-e1463
18 V Ficarra, S Sekulovic, F Zattoni, M Zazzera, G Novara. Why and how to evaluate chronic prostatic inflammation. Eur Urol Suppl. 2013;12:110-115 Crossref
19 A de La Taille. Therapeutic approach: the importance of controlling prostatic inflammation. Eur Urol Suppl. 2013;12:116-122 Crossref
20 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
21 GY Robert. Comparison of the effects of hexanic extract of Serenoa repens (Permixon) and tamsulosin on inflammation biomarkers in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Eur Urol Suppl. 2015;14:e1470-e1474
22 F Scaglione. How to choose the right Serenoa repens extract?. Eur Urol Suppl. 2015;14:e1464-e1469
23 G Laekeman, A Vlietinck. Assessment report on Serenoa repens (W. Bartram) small, fructus. European Medicines Agency Web site. http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2014/12/WC500179593.pdf. Accessed 21 May 2015
1 SJ Berry, DS Coffey, PC Walsh, LL Ewing. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-479
2 JC Nickel. Inflammation and benign prostatic hyperplasia. Urol Clin North Am. 2008;35:109-115 Crossref
3 W Bushman. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36:403-415 Crossref
4 B Chughtai, R Lee, A Te, S Kaplan. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011;13:147-150
5 F Di Silverio, V Gentile, A De Matteis, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43:164-175 Crossref
6 JC Nickel, CG Roehrborn, MP O'Leary, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54:1379-1384Crossref
7 G Robert, A Descazeaud, N Nicolaïew, et al. Inflammation in prostatic tissue is associated with symptomatic BPH, IPSS and prostate volume [abstract 1410]!. J Urol. 2009;181(Suppl):504 Crossref
8 B Djavan. The correlation between inflammation, BPH and prostate cancer. Eur Urol Suppl. 2009;8:863-864 Crossref
9 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
10 C De Nunzio, W Aronson, SJ Freedland, E Giovannucci, JK Parsons. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560-570 Crossref
11 V Ficarra. Is chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)?. BJU Int. 2013;112:421-422 Crossref
12 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
13 G Kramer, D Mitteregger, M Marberger. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?. Eur Urol. 2007;51:1202-1216 Crossref
14 PF Engelhardt, S Seklehner, H Brustmann, C Riedl, L Lusuardi. Tumor necrosis factor-α expression in patients with obstructive benign prostatic hyperplasia is associated with a higher incidence of asymptomatic inflammatory prostatitis NIH category IV and prostatic calcification. Scand J Urol. 2015 May 10;:1-7 [Epub ahead of print]. Crossref
15 R Bartoletti. Chronic inflammatory infiltrate and BPH: what do we know?. Eur Urol Suppl. 2013;12:99-102 Crossref
16 JA Schalken. Inflammation in the pathophysiology of benign prostatic hypertrophy. Eur Urol Suppl. 2015;14:e1455-e1458
17 JC Nickel. Role of prostatic inflammation in the clinical presentation of benign prostatic hyperplasia. Eur Urol Suppl. 2015;14:e1459-e1463
18 V Ficarra, S Sekulovic, F Zattoni, M Zazzera, G Novara. Why and how to evaluate chronic prostatic inflammation. Eur Urol Suppl. 2013;12:110-115 Crossref
19 A de La Taille. Therapeutic approach: the importance of controlling prostatic inflammation. Eur Urol Suppl. 2013;12:116-122 Crossref
20 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
21 GY Robert. Comparison of the effects of hexanic extract of Serenoa repens (Permixon) and tamsulosin on inflammation biomarkers in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Eur Urol Suppl. 2015;14:e1470-e1474
22 F Scaglione. How to choose the right Serenoa repens extract?. Eur Urol Suppl. 2015;14:e1464-e1469
23 G Laekeman, A Vlietinck. Assessment report on Serenoa repens (W. Bartram) small, fructus. European Medicines Agency Web site. http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2014/12/WC500179593.pdf. Accessed 21 May 2015
1 SJ Berry, DS Coffey, PC Walsh, LL Ewing. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-479
2 JC Nickel. Inflammation and benign prostatic hyperplasia. Urol Clin North Am. 2008;35:109-115 Crossref
3 W Bushman. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36:403-415 Crossref
4 B Chughtai, R Lee, A Te, S Kaplan. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011;13:147-150
5 F Di Silverio, V Gentile, A De Matteis, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43:164-175 Crossref
6 JC Nickel, CG Roehrborn, MP O'Leary, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54:1379-1384Crossref
7 G Robert, A Descazeaud, N Nicolaïew, et al. Inflammation in prostatic tissue is associated with symptomatic BPH, IPSS and prostate volume [abstract 1410]!. J Urol. 2009;181(Suppl):504 Crossref
8 B Djavan. The correlation between inflammation, BPH and prostate cancer. Eur Urol Suppl. 2009;8:863-864 Crossref
9 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
10 C De Nunzio, W Aronson, SJ Freedland, E Giovannucci, JK Parsons. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560-570 Crossref
11 V Ficarra. Is chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)?. BJU Int. 2013;112:421-422 Crossref
12 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
13 G Kramer, D Mitteregger, M Marberger. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?. Eur Urol. 2007;51:1202-1216 Crossref
14 PF Engelhardt, S Seklehner, H Brustmann, C Riedl, L Lusuardi. Tumor necrosis factor-α expression in patients with obstructive benign prostatic hyperplasia is associated with a higher incidence of asymptomatic inflammatory prostatitis NIH category IV and prostatic calcification. Scand J Urol. 2015 May 10;:1-7 [Epub ahead of print]. Crossref
15 R Bartoletti. Chronic inflammatory infiltrate and BPH: what do we know?. Eur Urol Suppl. 2013;12:99-102 Crossref
16 JA Schalken. Inflammation in the pathophysiology of benign prostatic hypertrophy. Eur Urol Suppl. 2015;14:e1455-e1458
17 JC Nickel. Role of prostatic inflammation in the clinical presentation of benign prostatic hyperplasia. Eur Urol Suppl. 2015;14:e1459-e1463
18 V Ficarra, S Sekulovic, F Zattoni, M Zazzera, G Novara. Why and how to evaluate chronic prostatic inflammation. Eur Urol Suppl. 2013;12:110-115 Crossref
19 A de La Taille. Therapeutic approach: the importance of controlling prostatic inflammation. Eur Urol Suppl. 2013;12:116-122 Crossref
20 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
21 GY Robert. Comparison of the effects of hexanic extract of Serenoa repens (Permixon) and tamsulosin on inflammation biomarkers in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Eur Urol Suppl. 2015;14:e1470-e1474
22 F Scaglione. How to choose the right Serenoa repens extract?. Eur Urol Suppl. 2015;14:e1464-e1469
23 G Laekeman, A Vlietinck. Assessment report on Serenoa repens (W. Bartram) small, fructus. European Medicines Agency Web site. http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2014/12/WC500179593.pdf. Accessed 21 May 2015
1 SJ Berry, DS Coffey, PC Walsh, LL Ewing. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-479
2 JC Nickel. Inflammation and benign prostatic hyperplasia. Urol Clin North Am. 2008;35:109-115 Crossref
3 W Bushman. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36:403-415 Crossref
4 B Chughtai, R Lee, A Te, S Kaplan. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011;13:147-150
5 F Di Silverio, V Gentile, A De Matteis, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43:164-175 Crossref
6 JC Nickel, CG Roehrborn, MP O'Leary, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54:1379-1384Crossref
7 G Robert, A Descazeaud, N Nicolaïew, et al. Inflammation in prostatic tissue is associated with symptomatic BPH, IPSS and prostate volume [abstract 1410]!. J Urol. 2009;181(Suppl):504 Crossref
8 B Djavan. The correlation between inflammation, BPH and prostate cancer. Eur Urol Suppl. 2009;8:863-864 Crossref
9 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
10 C De Nunzio, W Aronson, SJ Freedland, E Giovannucci, JK Parsons. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560-570 Crossref
11 V Ficarra. Is chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)?. BJU Int. 2013;112:421-422 Crossref
12 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
13 G Kramer, D Mitteregger, M Marberger. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?. Eur Urol. 2007;51:1202-1216 Crossref
14 PF Engelhardt, S Seklehner, H Brustmann, C Riedl, L Lusuardi. Tumor necrosis factor-α expression in patients with obstructive benign prostatic hyperplasia is associated with a higher incidence of asymptomatic inflammatory prostatitis NIH category IV and prostatic calcification. Scand J Urol. 2015 May 10;:1-7 [Epub ahead of print]. Crossref
15 R Bartoletti. Chronic inflammatory infiltrate and BPH: what do we know?. Eur Urol Suppl. 2013;12:99-102 Crossref
16 JA Schalken. Inflammation in the pathophysiology of benign prostatic hypertrophy. Eur Urol Suppl. 2015;14:e1455-e1458
17 JC Nickel. Role of prostatic inflammation in the clinical presentation of benign prostatic hyperplasia. Eur Urol Suppl. 2015;14:e1459-e1463
18 V Ficarra, S Sekulovic, F Zattoni, M Zazzera, G Novara. Why and how to evaluate chronic prostatic inflammation. Eur Urol Suppl. 2013;12:110-115 Crossref
19 A de La Taille. Therapeutic approach: the importance of controlling prostatic inflammation. Eur Urol Suppl. 2013;12:116-122 Crossref
20 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
21 GY Robert. Comparison of the effects of hexanic extract of Serenoa repens (Permixon) and tamsulosin on inflammation biomarkers in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Eur Urol Suppl. 2015;14:e1470-e1474
22 F Scaglione. How to choose the right Serenoa repens extract?. Eur Urol Suppl. 2015;14:e1464-e1469
23 G Laekeman, A Vlietinck. Assessment report on Serenoa repens (W. Bartram) small, fructus. European Medicines Agency Web site. http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2014/12/WC500179593.pdf. Accessed 21 May 2015
1 SJ Berry, DS Coffey, PC Walsh, LL Ewing. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-479
2 JC Nickel. Inflammation and benign prostatic hyperplasia. Urol Clin North Am. 2008;35:109-115 Crossref
3 W Bushman. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36:403-415 Crossref
4 B Chughtai, R Lee, A Te, S Kaplan. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011;13:147-150
5 F Di Silverio, V Gentile, A De Matteis, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43:164-175 Crossref
6 JC Nickel, CG Roehrborn, MP O'Leary, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54:1379-1384Crossref
7 G Robert, A Descazeaud, N Nicolaïew, et al. Inflammation in prostatic tissue is associated with symptomatic BPH, IPSS and prostate volume [abstract 1410]!. J Urol. 2009;181(Suppl):504 Crossref
8 B Djavan. The correlation between inflammation, BPH and prostate cancer. Eur Urol Suppl. 2009;8:863-864 Crossref
9 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
10 C De Nunzio, W Aronson, SJ Freedland, E Giovannucci, JK Parsons. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560-570 Crossref
11 V Ficarra. Is chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)?. BJU Int. 2013;112:421-422 Crossref
12 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
13 G Kramer, D Mitteregger, M Marberger. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?. Eur Urol. 2007;51:1202-1216 Crossref
14 PF Engelhardt, S Seklehner, H Brustmann, C Riedl, L Lusuardi. Tumor necrosis factor-α expression in patients with obstructive benign prostatic hyperplasia is associated with a higher incidence of asymptomatic inflammatory prostatitis NIH category IV and prostatic calcification. Scand J Urol. 2015 May 10;:1-7 [Epub ahead of print]. Crossref
15 R Bartoletti. Chronic inflammatory infiltrate and BPH: what do we know?. Eur Urol Suppl. 2013;12:99-102 Crossref
16 JA Schalken. Inflammation in the pathophysiology of benign prostatic hypertrophy. Eur Urol Suppl. 2015;14:e1455-e1458
17 JC Nickel. Role of prostatic inflammation in the clinical presentation of benign prostatic hyperplasia. Eur Urol Suppl. 2015;14:e1459-e1463
18 V Ficarra, S Sekulovic, F Zattoni, M Zazzera, G Novara. Why and how to evaluate chronic prostatic inflammation. Eur Urol Suppl. 2013;12:110-115 Crossref
19 A de La Taille. Therapeutic approach: the importance of controlling prostatic inflammation. Eur Urol Suppl. 2013;12:116-122 Crossref
20 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
21 GY Robert. Comparison of the effects of hexanic extract of Serenoa repens (Permixon) and tamsulosin on inflammation biomarkers in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Eur Urol Suppl. 2015;14:e1470-e1474
22 F Scaglione. How to choose the right Serenoa repens extract?. Eur Urol Suppl. 2015;14:e1464-e1469
23 G Laekeman, A Vlietinck. Assessment report on Serenoa repens (W. Bartram) small, fructus. European Medicines Agency Web site. http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2014/12/WC500179593.pdf. Accessed 21 May 2015
1 SJ Berry, DS Coffey, PC Walsh, LL Ewing. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-479
2 JC Nickel. Inflammation and benign prostatic hyperplasia. Urol Clin North Am. 2008;35:109-115 Crossref
3 W Bushman. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36:403-415 Crossref
4 B Chughtai, R Lee, A Te, S Kaplan. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011;13:147-150
5 F Di Silverio, V Gentile, A De Matteis, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43:164-175 Crossref
6 JC Nickel, CG Roehrborn, MP O'Leary, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54:1379-1384Crossref
7 G Robert, A Descazeaud, N Nicolaïew, et al. Inflammation in prostatic tissue is associated with symptomatic BPH, IPSS and prostate volume [abstract 1410]!. J Urol. 2009;181(Suppl):504 Crossref
8 B Djavan. The correlation between inflammation, BPH and prostate cancer. Eur Urol Suppl. 2009;8:863-864 Crossref
9 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
10 C De Nunzio, W Aronson, SJ Freedland, E Giovannucci, JK Parsons. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560-570 Crossref
11 V Ficarra. Is chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)?. BJU Int. 2013;112:421-422 Crossref
12 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
13 G Kramer, D Mitteregger, M Marberger. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?. Eur Urol. 2007;51:1202-1216 Crossref
14 PF Engelhardt, S Seklehner, H Brustmann, C Riedl, L Lusuardi. Tumor necrosis factor-α expression in patients with obstructive benign prostatic hyperplasia is associated with a higher incidence of asymptomatic inflammatory prostatitis NIH category IV and prostatic calcification. Scand J Urol. 2015 May 10;:1-7 [Epub ahead of print]. Crossref
15 R Bartoletti. Chronic inflammatory infiltrate and BPH: what do we know?. Eur Urol Suppl. 2013;12:99-102 Crossref
16 JA Schalken. Inflammation in the pathophysiology of benign prostatic hypertrophy. Eur Urol Suppl. 2015;14:e1455-e1458
17 JC Nickel. Role of prostatic inflammation in the clinical presentation of benign prostatic hyperplasia. Eur Urol Suppl. 2015;14:e1459-e1463
18 V Ficarra, S Sekulovic, F Zattoni, M Zazzera, G Novara. Why and how to evaluate chronic prostatic inflammation. Eur Urol Suppl. 2013;12:110-115 Crossref
19 A de La Taille. Therapeutic approach: the importance of controlling prostatic inflammation. Eur Urol Suppl. 2013;12:116-122 Crossref
20 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
21 GY Robert. Comparison of the effects of hexanic extract of Serenoa repens (Permixon) and tamsulosin on inflammation biomarkers in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Eur Urol Suppl. 2015;14:e1470-e1474
22 F Scaglione. How to choose the right Serenoa repens extract?. Eur Urol Suppl. 2015;14:e1464-e1469
23 G Laekeman, A Vlietinck. Assessment report on Serenoa repens (W. Bartram) small, fructus. European Medicines Agency Web site. http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2014/12/WC500179593.pdf. Accessed 21 May 2015
1 SJ Berry, DS Coffey, PC Walsh, LL Ewing. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-479
2 JC Nickel. Inflammation and benign prostatic hyperplasia. Urol Clin North Am. 2008;35:109-115 Crossref
3 W Bushman. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36:403-415 Crossref
4 B Chughtai, R Lee, A Te, S Kaplan. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011;13:147-150
5 F Di Silverio, V Gentile, A De Matteis, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43:164-175 Crossref
6 JC Nickel, CG Roehrborn, MP O'Leary, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54:1379-1384Crossref
7 G Robert, A Descazeaud, N Nicolaïew, et al. Inflammation in prostatic tissue is associated with symptomatic BPH, IPSS and prostate volume [abstract 1410]!. J Urol. 2009;181(Suppl):504 Crossref
8 B Djavan. The correlation between inflammation, BPH and prostate cancer. Eur Urol Suppl. 2009;8:863-864 Crossref
9 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
10 C De Nunzio, W Aronson, SJ Freedland, E Giovannucci, JK Parsons. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560-570 Crossref
11 V Ficarra. Is chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)?. BJU Int. 2013;112:421-422 Crossref
12 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
13 G Kramer, D Mitteregger, M Marberger. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?. Eur Urol. 2007;51:1202-1216 Crossref
14 PF Engelhardt, S Seklehner, H Brustmann, C Riedl, L Lusuardi. Tumor necrosis factor-α expression in patients with obstructive benign prostatic hyperplasia is associated with a higher incidence of asymptomatic inflammatory prostatitis NIH category IV and prostatic calcification. Scand J Urol. 2015 May 10;:1-7 [Epub ahead of print]. Crossref
15 R Bartoletti. Chronic inflammatory infiltrate and BPH: what do we know?. Eur Urol Suppl. 2013;12:99-102 Crossref
16 JA Schalken. Inflammation in the pathophysiology of benign prostatic hypertrophy. Eur Urol Suppl. 2015;14:e1455-e1458
17 JC Nickel. Role of prostatic inflammation in the clinical presentation of benign prostatic hyperplasia. Eur Urol Suppl. 2015;14:e1459-e1463
18 V Ficarra, S Sekulovic, F Zattoni, M Zazzera, G Novara. Why and how to evaluate chronic prostatic inflammation. Eur Urol Suppl. 2013;12:110-115 Crossref
19 A de La Taille. Therapeutic approach: the importance of controlling prostatic inflammation. Eur Urol Suppl. 2013;12:116-122 Crossref
20 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
21 GY Robert. Comparison of the effects of hexanic extract of Serenoa repens (Permixon) and tamsulosin on inflammation biomarkers in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Eur Urol Suppl. 2015;14:e1470-e1474
22 F Scaglione. How to choose the right Serenoa repens extract?. Eur Urol Suppl. 2015;14:e1464-e1469
23 G Laekeman, A Vlietinck. Assessment report on Serenoa repens (W. Bartram) small, fructus. European Medicines Agency Web site. http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2014/12/WC500179593.pdf. Accessed 21 May 2015
1 SJ Berry, DS Coffey, PC Walsh, LL Ewing. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-479
2 JC Nickel. Inflammation and benign prostatic hyperplasia. Urol Clin North Am. 2008;35:109-115 Crossref
3 W Bushman. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36:403-415 Crossref
4 B Chughtai, R Lee, A Te, S Kaplan. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011;13:147-150
5 F Di Silverio, V Gentile, A De Matteis, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43:164-175 Crossref
6 JC Nickel, CG Roehrborn, MP O'Leary, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54:1379-1384Crossref
7 G Robert, A Descazeaud, N Nicolaïew, et al. Inflammation in prostatic tissue is associated with symptomatic BPH, IPSS and prostate volume [abstract 1410]!. J Urol. 2009;181(Suppl):504 Crossref
8 B Djavan. The correlation between inflammation, BPH and prostate cancer. Eur Urol Suppl. 2009;8:863-864 Crossref
9 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
10 C De Nunzio, W Aronson, SJ Freedland, E Giovannucci, JK Parsons. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560-570 Crossref
11 V Ficarra. Is chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)?. BJU Int. 2013;112:421-422 Crossref
12 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
13 G Kramer, D Mitteregger, M Marberger. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?. Eur Urol. 2007;51:1202-1216 Crossref
14 PF Engelhardt, S Seklehner, H Brustmann, C Riedl, L Lusuardi. Tumor necrosis factor-α expression in patients with obstructive benign prostatic hyperplasia is associated with a higher incidence of asymptomatic inflammatory prostatitis NIH category IV and prostatic calcification. Scand J Urol. 2015 May 10;:1-7 [Epub ahead of print]. Crossref
15 R Bartoletti. Chronic inflammatory infiltrate and BPH: what do we know?. Eur Urol Suppl. 2013;12:99-102 Crossref
16 JA Schalken. Inflammation in the pathophysiology of benign prostatic hypertrophy. Eur Urol Suppl. 2015;14:e1455-e1458
17 JC Nickel. Role of prostatic inflammation in the clinical presentation of benign prostatic hyperplasia. Eur Urol Suppl. 2015;14:e1459-e1463
18 V Ficarra, S Sekulovic, F Zattoni, M Zazzera, G Novara. Why and how to evaluate chronic prostatic inflammation. Eur Urol Suppl. 2013;12:110-115 Crossref
19 A de La Taille. Therapeutic approach: the importance of controlling prostatic inflammation. Eur Urol Suppl. 2013;12:116-122 Crossref
20 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
21 GY Robert. Comparison of the effects of hexanic extract of Serenoa repens (Permixon) and tamsulosin on inflammation biomarkers in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Eur Urol Suppl. 2015;14:e1470-e1474
22 F Scaglione. How to choose the right Serenoa repens extract?. Eur Urol Suppl. 2015;14:e1464-e1469
23 G Laekeman, A Vlietinck. Assessment report on Serenoa repens (W. Bartram) small, fructus. European Medicines Agency Web site. http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2014/12/WC500179593.pdf. Accessed 21 May 2015
1 SJ Berry, DS Coffey, PC Walsh, LL Ewing. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-479
2 JC Nickel. Inflammation and benign prostatic hyperplasia. Urol Clin North Am. 2008;35:109-115 Crossref
3 W Bushman. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36:403-415 Crossref
4 B Chughtai, R Lee, A Te, S Kaplan. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011;13:147-150
5 F Di Silverio, V Gentile, A De Matteis, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43:164-175 Crossref
6 JC Nickel, CG Roehrborn, MP O'Leary, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54:1379-1384Crossref
7 G Robert, A Descazeaud, N Nicolaïew, et al. Inflammation in prostatic tissue is associated with symptomatic BPH, IPSS and prostate volume [abstract 1410]!. J Urol. 2009;181(Suppl):504 Crossref
8 B Djavan. The correlation between inflammation, BPH and prostate cancer. Eur Urol Suppl. 2009;8:863-864 Crossref
9 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
10 C De Nunzio, W Aronson, SJ Freedland, E Giovannucci, JK Parsons. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560-570 Crossref
11 V Ficarra. Is chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)?. BJU Int. 2013;112:421-422 Crossref
12 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
13 G Kramer, D Mitteregger, M Marberger. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?. Eur Urol. 2007;51:1202-1216 Crossref
14 PF Engelhardt, S Seklehner, H Brustmann, C Riedl, L Lusuardi. Tumor necrosis factor-α expression in patients with obstructive benign prostatic hyperplasia is associated with a higher incidence of asymptomatic inflammatory prostatitis NIH category IV and prostatic calcification. Scand J Urol. 2015 May 10;:1-7 [Epub ahead of print]. Crossref
15 R Bartoletti. Chronic inflammatory infiltrate and BPH: what do we know?. Eur Urol Suppl. 2013;12:99-102 Crossref
16 JA Schalken. Inflammation in the pathophysiology of benign prostatic hypertrophy. Eur Urol Suppl. 2015;14:e1455-e1458
17 JC Nickel. Role of prostatic inflammation in the clinical presentation of benign prostatic hyperplasia. Eur Urol Suppl. 2015;14:e1459-e1463
18 V Ficarra, S Sekulovic, F Zattoni, M Zazzera, G Novara. Why and how to evaluate chronic prostatic inflammation. Eur Urol Suppl. 2013;12:110-115 Crossref
19 A de La Taille. Therapeutic approach: the importance of controlling prostatic inflammation. Eur Urol Suppl. 2013;12:116-122 Crossref
20 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
21 GY Robert. Comparison of the effects of hexanic extract of Serenoa repens (Permixon) and tamsulosin on inflammation biomarkers in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Eur Urol Suppl. 2015;14:e1470-e1474
22 F Scaglione. How to choose the right Serenoa repens extract?. Eur Urol Suppl. 2015;14:e1464-e1469
23 G Laekeman, A Vlietinck. Assessment report on Serenoa repens (W. Bartram) small, fructus. European Medicines Agency Web site. http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2014/12/WC500179593.pdf. Accessed 21 May 2015
1 SJ Berry, DS Coffey, PC Walsh, LL Ewing. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-479
2 JC Nickel. Inflammation and benign prostatic hyperplasia. Urol Clin North Am. 2008;35:109-115 Crossref
3 W Bushman. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36:403-415 Crossref
4 B Chughtai, R Lee, A Te, S Kaplan. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011;13:147-150
5 F Di Silverio, V Gentile, A De Matteis, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43:164-175 Crossref
6 JC Nickel, CG Roehrborn, MP O'Leary, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54:1379-1384Crossref
7 G Robert, A Descazeaud, N Nicolaïew, et al. Inflammation in prostatic tissue is associated with symptomatic BPH, IPSS and prostate volume [abstract 1410]!. J Urol. 2009;181(Suppl):504 Crossref
8 B Djavan. The correlation between inflammation, BPH and prostate cancer. Eur Urol Suppl. 2009;8:863-864 Crossref
9 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
10 C De Nunzio, W Aronson, SJ Freedland, E Giovannucci, JK Parsons. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560-570 Crossref
11 V Ficarra. Is chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)?. BJU Int. 2013;112:421-422 Crossref
12 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
13 G Kramer, D Mitteregger, M Marberger. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?. Eur Urol. 2007;51:1202-1216 Crossref
14 PF Engelhardt, S Seklehner, H Brustmann, C Riedl, L Lusuardi. Tumor necrosis factor-α expression in patients with obstructive benign prostatic hyperplasia is associated with a higher incidence of asymptomatic inflammatory prostatitis NIH category IV and prostatic calcification. Scand J Urol. 2015 May 10;:1-7 [Epub ahead of print]. Crossref
15 R Bartoletti. Chronic inflammatory infiltrate and BPH: what do we know?. Eur Urol Suppl. 2013;12:99-102 Crossref
16 JA Schalken. Inflammation in the pathophysiology of benign prostatic hypertrophy. Eur Urol Suppl. 2015;14:e1455-e1458
17 JC Nickel. Role of prostatic inflammation in the clinical presentation of benign prostatic hyperplasia. Eur Urol Suppl. 2015;14:e1459-e1463
18 V Ficarra, S Sekulovic, F Zattoni, M Zazzera, G Novara. Why and how to evaluate chronic prostatic inflammation. Eur Urol Suppl. 2013;12:110-115 Crossref
19 A de La Taille. Therapeutic approach: the importance of controlling prostatic inflammation. Eur Urol Suppl. 2013;12:116-122 Crossref
20 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
21 GY Robert. Comparison of the effects of hexanic extract of Serenoa repens (Permixon) and tamsulosin on inflammation biomarkers in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Eur Urol Suppl. 2015;14:e1470-e1474
22 F Scaglione. How to choose the right Serenoa repens extract?. Eur Urol Suppl. 2015;14:e1464-e1469
23 G Laekeman, A Vlietinck. Assessment report on Serenoa repens (W. Bartram) small, fructus. European Medicines Agency Web site. http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2014/12/WC500179593.pdf. Accessed 21 May 2015
1 SJ Berry, DS Coffey, PC Walsh, LL Ewing. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-479
2 JC Nickel. Inflammation and benign prostatic hyperplasia. Urol Clin North Am. 2008;35:109-115 Crossref
3 W Bushman. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36:403-415 Crossref
4 B Chughtai, R Lee, A Te, S Kaplan. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011;13:147-150
5 F Di Silverio, V Gentile, A De Matteis, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43:164-175 Crossref
6 JC Nickel, CG Roehrborn, MP O'Leary, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54:1379-1384Crossref
7 G Robert, A Descazeaud, N Nicolaïew, et al. Inflammation in prostatic tissue is associated with symptomatic BPH, IPSS and prostate volume [abstract 1410]!. J Urol. 2009;181(Suppl):504 Crossref
8 B Djavan. The correlation between inflammation, BPH and prostate cancer. Eur Urol Suppl. 2009;8:863-864 Crossref
9 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
10 C De Nunzio, W Aronson, SJ Freedland, E Giovannucci, JK Parsons. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560-570 Crossref
11 V Ficarra. Is chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)?. BJU Int. 2013;112:421-422 Crossref
12 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
13 G Kramer, D Mitteregger, M Marberger. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?. Eur Urol. 2007;51:1202-1216 Crossref
14 PF Engelhardt, S Seklehner, H Brustmann, C Riedl, L Lusuardi. Tumor necrosis factor-α expression in patients with obstructive benign prostatic hyperplasia is associated with a higher incidence of asymptomatic inflammatory prostatitis NIH category IV and prostatic calcification. Scand J Urol. 2015 May 10;:1-7 [Epub ahead of print]. Crossref
15 R Bartoletti. Chronic inflammatory infiltrate and BPH: what do we know?. Eur Urol Suppl. 2013;12:99-102 Crossref
16 JA Schalken. Inflammation in the pathophysiology of benign prostatic hypertrophy. Eur Urol Suppl. 2015;14:e1455-e1458
17 JC Nickel. Role of prostatic inflammation in the clinical presentation of benign prostatic hyperplasia. Eur Urol Suppl. 2015;14:e1459-e1463
18 V Ficarra, S Sekulovic, F Zattoni, M Zazzera, G Novara. Why and how to evaluate chronic prostatic inflammation. Eur Urol Suppl. 2013;12:110-115 Crossref
19 A de La Taille. Therapeutic approach: the importance of controlling prostatic inflammation. Eur Urol Suppl. 2013;12:116-122 Crossref
20 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
21 GY Robert. Comparison of the effects of hexanic extract of Serenoa repens (Permixon) and tamsulosin on inflammation biomarkers in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Eur Urol Suppl. 2015;14:e1470-e1474
22 F Scaglione. How to choose the right Serenoa repens extract?. Eur Urol Suppl. 2015;14:e1464-e1469
23 G Laekeman, A Vlietinck. Assessment report on Serenoa repens (W. Bartram) small, fructus. European Medicines Agency Web site. http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2014/12/WC500179593.pdf. Accessed 21 May 2015
1 SJ Berry, DS Coffey, PC Walsh, LL Ewing. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-479
2 JC Nickel. Inflammation and benign prostatic hyperplasia. Urol Clin North Am. 2008;35:109-115 Crossref
3 W Bushman. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36:403-415 Crossref
4 B Chughtai, R Lee, A Te, S Kaplan. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011;13:147-150
5 F Di Silverio, V Gentile, A De Matteis, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43:164-175 Crossref
6 JC Nickel, CG Roehrborn, MP O'Leary, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54:1379-1384Crossref
7 G Robert, A Descazeaud, N Nicolaïew, et al. Inflammation in prostatic tissue is associated with symptomatic BPH, IPSS and prostate volume [abstract 1410]!. J Urol. 2009;181(Suppl):504 Crossref
8 B Djavan. The correlation between inflammation, BPH and prostate cancer. Eur Urol Suppl. 2009;8:863-864 Crossref
9 G Gandaglia, A Briganti, P Gontero, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432-441 Crossref
10 C De Nunzio, W Aronson, SJ Freedland, E Giovannucci, JK Parsons. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560-570 Crossref
11 V Ficarra. Is chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)?. BJU Int. 2013;112:421-422 Crossref
12 G Robert, F Smit, D Hessels, et al. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011;71:1701-1709 Crossref
13 G Kramer, D Mitteregger, M Marberger. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?. Eur Urol. 2007;51:1202-1216 Crossref
14 PF Engelhardt, S Seklehner, H Brustmann, C Riedl, L Lusuardi. Tumor necrosis factor-α expression in patients with obstructive benign prostatic hyperplasia is associated with a higher incidence of asymptomatic inflammatory prostatitis NIH category IV and prostatic calcification. Scand J Urol. 2015 May 10;:1-7 [Epub ahead of print]. Crossref
15 R Bartoletti. Chronic inflammatory infiltrate and BPH: what do we know?. Eur Urol Suppl. 2013;12:99-102 Crossref
16 JA Schalken. Inflammation in the pathophysiology of benign prostatic hypertrophy. Eur Urol Suppl. 2015;14:e1455-e1458
17 JC Nickel. Role of prostatic inflammation in the clinical presentation of benign prostatic hyperplasia. Eur Urol Suppl. 2015;14:e1459-e1463
18 V Ficarra, S Sekulovic, F Zattoni, M Zazzera, G Novara. Why and how to evaluate chronic prostatic inflammation. Eur Urol Suppl. 2013;12:110-115 Crossref
19 A de La Taille. Therapeutic approach: the importance of controlling prostatic inflammation. Eur Urol Suppl. 2013;12:116-122 Crossref
20 A Latil, MT Pétrissans, J Rouquet, G Robert, A de la Taille. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate. 2015;75:1857-1867
21 GY Robert. Comparison of the effects of hexanic extract of Serenoa repens (Permixon) and tamsulosin on inflammation biomarkers in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Eur Urol Suppl. 2015;14:e1470-e1474
22 F Scaglione. How to choose the right Serenoa repens extract?. Eur Urol Suppl. 2015;14:e1464-e1469
23 G Laekeman, A Vlietinck. Assessment report on Serenoa repens (W. Bartram) small, fructus. European Medicines Agency Web site. http://www.ema.europa.eu/docs/en_GB/document_library/Herbal_-_HMPC_assessment_report/2014/12/WC500179593.pdf. Accessed 21 May 2015
